The marked increase in incidence and mortality in endometrial cancer over the last two decades is driven in part by rising rates of higher grade, more aggressive endometrial cancers with mutations in TP53, uterine serous cancers and their dedifferentiated component, uterine carcinosarcomas (collectively USC). USC rates have been increasing among all racial and ethnic groups, with higher rates of this aggressive uterine cancer in Black women. The National Cancer Institute (NCI) hosted a workshop in June 2023 to examine the diverse aspects of USC across epidemiology, biology, and molecular genetics, and to advance knowledge from basic to preclinical and translational efforts. Key stakeholders came together including basic scientists, clinical investigators, and patient advocates to identify critical research gaps that, when addressed, would facilitate more comprehensive and rapid progress in understanding and ultimately treating USC across all patients. NCI released a supplemental funding opportunity (NOT-CA-24-044) in Spring 2024 to facilitate rapid translation of these recommendations.

中文翻译：

---

子宫浆液性癌的不同方面：关于研究现状和发展机会的 NCI 研讨会。


在过去二十年中，子宫内膜癌的发病率和死亡率显着增加，部分原因是具有 TP53 突变的更高级别、更具侵袭性的子宫内膜癌、子宫浆液性癌及其分化成分子宫癌肉瘤（统称为 USC）的发病率上升。所有种族和族裔群体的 USC 发病率都在增加，黑人女性患这种侵袭性子宫癌的发病率更高。美国国家癌症研究所 （NCI） 于 2023 年 6 月举办了一次研讨会，以研究南加州大学在流行病学、生物学和分子遗传学方面的各个方面，并将知识从基础推进到临床前和转化工作。包括基础科学家、临床研究人员和患者倡导者在内的主要利益相关者齐聚一堂，以确定关键的研究差距，这些差距得到解决后，将有助于在理解和最终治疗所有患者的 USC 方面取得更全面、更快速的进展。NCI 于 2024 年春季发布了补充资助机会 （NOT-CA-24-044），以促进这些建议的快速翻译。